Pillora Editorial Board & Clinical Governance Standards
Pillora is committed to 100% scientific objectivity, medical precision, and patient safety. Our clinical algorithms, bioequivalence matching rules, and research publications are governed directly by licensed Pakistani clinical pharmacists registered with the Pharmacy Council of Pakistan.
Clinical Review Board Leadership
Dr. Sarah Tariq, Pharm.D, M.Phil Clinical Pharmacy
Specialist in Clinical Pharmacokinetics and Bioequivalence Assessment. Over 8 years of clinical hospital pharmacy experience across tertiary care institutions in Lahore. Supervises therapeutic equivalence algorithms, research publications, and clinical drug safety warnings on Pillora.
Dr. Ayesha Tariq, Pharm.D, RPh
Expert in drug regulatory gazette mapping and hospital drug information systems. Oversees the rigorous cross-referencing of active DRAP registrations and price ceilings against official federal gazettes.
Dr. M. Fahad, Pharm.D, RPh
Community pharmacist and healthcare advocate. Audits pack-size unit cost normalization algorithms, ensuring tablets, capsules, and liquids reflect genuine retail per-unit prices.
Editorial Independence & Ethics Charter
- Zero Pharmaceutical Commercial Influence: Pillora accepts no sponsorships, advertising fees, or endorsements from any pharmaceutical manufacturer. Algorithm rankings reflect genuine price-per-unit bioequivalence solely.
- No Medicine Sales or Commission: Pillora is not an online pharmacy. We do not sell medications, broker orders, or take referral fees. We are an independent consumer transparency utility.
- Rigorous Patient Safety Guardrails: We explicitly flag narrow-therapeutic-index drugs where brand switching without laboratory and clinical monitoring is medically inadvisable.